Compare Gilead Sciences, Inc. (GILD) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SiTime Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.18 (market cap $163.51B), while SiTime Corporation trades at $576.03 (market cap $18.34B). The key difference: Gilead Sciences, Inc. is far larger — about 8.9× SiTime Corporation's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| GILD | SITM | |
|---|---|---|
Market Cap | $163.51B | $18.34B |
Sector | Health | Technology |
52-Week High | $155.80 | $901.60 |
52-Week Low | $108.22 | $190.16 |
Enterprise Value | $178.05B | $17.56B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SITM trades at $583.36, down 6.49% today, amid a bearish technical signal. The stock shows strong earnings beats in recent quarters but negative profitability margins. Recent news includes the completion of Renesas' timing business acquisition and strong AI-driven revenue growth. Cash flow trends indicate heavy investment activity in 2025, with a projected improvement in 2026.
Outlook is mixed; analyst consensus is strongly bullish with a $825 price target, but high valuation ratios and negative margins pose risks. The stock's near-term direction may hinge on Q2 2026 earnings due August 5, 2026, and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
